Cellular immunotherapy for neuroblastoma: A review of current vaccine and adoptive T cell therapeutics

C. U. Louis, M. K. Brenner

Research output: Contribution to journalReview article

20 Scopus citations

Abstract

Immunotherapy is an attractive option for patients with high risk neuroblastoma due to their poor long-term survival rates after conventional treatment. Neuroblastoma cells are derived from the embryonic neural crest and therefore express tumor antigens not widely seen in normal cells, making them potential targets for immunologic attack. There is already considerable experience with monoclonal antibodies that target these tumor associated antigens, and in this review we focus on more exploratory approaches, using tumor vaccines and adoptive transfer of tumor-directed T cells.

Original languageEnglish (US)
Pages (from-to)424-429
Number of pages6
JournalCurrent Pharmaceutical Design
Volume15
Issue number4
DOIs
StatePublished - 2009

Keywords

  • Adoptive T cell transfer
  • Chimeric antigen receptors
  • Immunotheraphy
  • Neuroblastoma
  • Vaccine trials

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Fingerprint Dive into the research topics of 'Cellular immunotherapy for neuroblastoma: A review of current vaccine and adoptive T cell therapeutics'. Together they form a unique fingerprint.

Cite this